FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2100035948> ?p ?o ?g. }

• W2100035948 endingPage "1855" @default.
• W2100035948 startingPage "1855" @default.
• W2100035948 abstract "Shikonin-loaded antibody-armed nanoparticles for targeted therapy of ovarian cancer Efthymia-Iliana Matthaiou,1,2 Jaleh Barar,1,3 Raphael Sandaltzopoulos,2 Chunsheng Li,1 George Coukos,1,4 Yadollah Omidi1,3 1Ovarian Cancer Research Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; 2Department of Molecular Biology and Genetics, Democritus University of Thrace, Alexandroupolis, Greece; 3Research Center for Pharmaceutical Nanotechnology, Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran; 4Ludwig Institute for Cancer Research, University of Lausanne, Lausanne, Switzerland Abstract: Conventional chemotherapy of ovarian cancer often fails because of initiation of drug resistance and/or side effects and trace of untouched remaining cancerous cells. This highlights an urgent need for advanced targeted therapies for effective remediation of the disease using a cytotoxic agent with immunomodulatory effects, such as shikonin (SHK). Based on preliminary experiments, we found SHK to be profoundly toxic in ovarian epithelial cancer cells (OVCAR-5 and ID8 cells) as well as in normal ovarian IOSE-398 cells, endothelial MS1 cells, and lymphocytes. To limit its cytotoxic impact solely to tumor cells within the tumor microenvironment (TME), we aimed to engineer SHK as polymeric nanoparticles (NPs) with targeting moiety toward tumor microvasculature. To this end, using single/double emulsion solvent evaporation/diffusion technique with sonication, we formulated biodegradable NPs of poly(lactic-co-glycolic acid) (PLGA) loaded with SHK. The surface of NPs was further decorated with solubilizing agent polyethylene glycol (PEG) and tumor endothelial marker 1 (TEM1)/endosialin-targeting antibody (Ab) through carbodiimide/N-hydroxysuccinimide chemistry. Having characterized the physicochemical and morphological properties of NPs, we studied their drug-release profiles using various kinetic models. The biological impact of NPs was also evaluated in tumor-associated endothelial MS1 cells, primary lymphocytes, and epithelial ovarian cancer OVCAR-5 cells. Based on particle size analysis and electron microscopy, the engineered NPs showed a smooth spherical shape with size range of 120 to 250 nm and zeta potential value of -30 to -40 mV. Drug entrapment efficiency was ~80%–90%, which was reduced to ~50%–60% upon surface decoration with PEG and Ab. The liberation of SHK from NPs showed a sustained-release profile that was best fitted with Wagner log-probability model. Fluorescence microscopy and flow cytometry analysis showed active interaction of Ab-armed NPs with TEM1-positive MS1 cells, but not with TEM1-negative MS1 cells. While exposure of the PEGylated NPs for 2 hours was not toxic to lymphocytes, long-term exposure of the Ab-armed and PEGylated NPs was significantly toxic to TEM1-positive MS1 cells and OVCAR-5 cells. Based on these findings, we propose SHK-loaded Ab-armed PEGylated PLGA NPs as a novel nanomedicine for targeted therapy of solid tumors. Keywords: nanomedicine, nanoparticle, ovarian cancer, shikonin, targeted therapy, tumor vasculature" @default.
• W2100035948 created "2016-06-24" @default.
• W2100035948 creator A5001793981 @default.
• W2100035948 creator A5028913501 @default.
• W2100035948 creator A5031279238 @default.
• W2100035948 creator A5041800046 @default.
• W2100035948 creator A5067954504 @default.
• W2100035948 creator A5074590917 @default.
• W2100035948 date "2014-04-01" @default.
• W2100035948 modified "2023-09-23" @default.
• W2100035948 title "Shikonin-loaded antibody-armed nanoparticles for targeted therapy of ovarian cancer" @default.
• W2100035948 cites W114019716 @default.
• W2100035948 cites W1483346783 @default.
• W2100035948 cites W1556912674 @default.
• W2100035948 cites W1643757801 @default.
• W2100035948 cites W1971425380 @default.
• W2100035948 cites W1972970472 @default.
• W2100035948 cites W1979947924 @default.
• W2100035948 cites W1986967025 @default.
• W2100035948 cites W1990359801 @default.
• W2100035948 cites W1990511776 @default.
• W2100035948 cites W1995709551 @default.
• W2100035948 cites W2003090882 @default.
• W2100035948 cites W2006335846 @default.
• W2100035948 cites W2009066160 @default.
• W2100035948 cites W2012328517 @default.
• W2100035948 cites W2016034696 @default.
• W2100035948 cites W2016690645 @default.
• W2100035948 cites W2017367722 @default.
• W2100035948 cites W2019541940 @default.
• W2100035948 cites W2027542963 @default.
• W2100035948 cites W2043320573 @default.
• W2100035948 cites W2047389902 @default.
• W2100035948 cites W2049035021 @default.
• W2100035948 cites W2051543414 @default.
• W2100035948 cites W2056712783 @default.
• W2100035948 cites W2059736531 @default.
• W2100035948 cites W2063863065 @default.
• W2100035948 cites W2065472817 @default.
• W2100035948 cites W2075300550 @default.
• W2100035948 cites W2076022365 @default.
• W2100035948 cites W2078532650 @default.
• W2100035948 cites W2079931546 @default.
• W2100035948 cites W2090146671 @default.
• W2100035948 cites W2098861374 @default.
• W2100035948 cites W2099692303 @default.
• W2100035948 cites W2100151202 @default.
• W2100035948 cites W2103093128 @default.
• W2100035948 cites W2104062750 @default.
• W2100035948 cites W2105343186 @default.
• W2100035948 cites W2112687126 @default.
• W2100035948 cites W2115496672 @default.
• W2100035948 cites W2137634849 @default.
• W2100035948 cites W2138814678 @default.
• W2100035948 cites W2144260153 @default.
• W2100035948 cites W2154020108 @default.
• W2100035948 cites W2154881868 @default.
• W2100035948 cites W2167948024 @default.
• W2100035948 cites W2170179169 @default.
• W2100035948 cites W2171289705 @default.
• W2100035948 cites W2181509337 @default.
• W2100035948 cites W2260440448 @default.
• W2100035948 cites W2327445019 @default.
• W2100035948 cites W3036016153 @default.
• W2100035948 doi "https://doi.org/10.2147/ijn.s51880" @default.
• W2100035948 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3998853" @default.
• W2100035948 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24790428" @default.
• W2100035948 hasPublicationYear "2014" @default.
• W2100035948 type Work @default.
• W2100035948 sameAs 2100035948 @default.
• W2100035948 citedByCount "30" @default.
• W2100035948 countsByYear W21000359482014 @default.
• W2100035948 countsByYear W21000359482015 @default.
• W2100035948 countsByYear W21000359482016 @default.
• W2100035948 countsByYear W21000359482017 @default.
• W2100035948 countsByYear W21000359482018 @default.
• W2100035948 countsByYear W21000359482019 @default.
• W2100035948 countsByYear W21000359482021 @default.
• W2100035948 countsByYear W21000359482022 @default.
• W2100035948 countsByYear W21000359482023 @default.
• W2100035948 crossrefType "journal-article" @default.
• W2100035948 hasAuthorship W2100035948A5001793981 @default.
• W2100035948 hasAuthorship W2100035948A5028913501 @default.
• W2100035948 hasAuthorship W2100035948A5031279238 @default.
• W2100035948 hasAuthorship W2100035948A5041800046 @default.
• W2100035948 hasAuthorship W2100035948A5067954504 @default.
• W2100035948 hasAuthorship W2100035948A5074590917 @default.
• W2100035948 hasBestOaLocation W21000359481 @default.
• W2100035948 hasConcept C121608353 @default.
• W2100035948 hasConcept C126322002 @default.
• W2100035948 hasConcept C154317977 @default.
• W2100035948 hasConcept C185592680 @default.
• W2100035948 hasConcept C202751555 @default.
• W2100035948 hasConcept C2776107976 @default.
• W2100035948 hasConcept C2780427987 @default.
• W2100035948 hasConcept C502942594 @default.
• W2100035948 hasConcept C55493867 @default.
• W2100035948 hasConcept C71924100 @default.

• next